



## **Final Appraisal Recommendation**

### **Atazanavir (Reyataz<sup>®</sup>▼) capsules**

**Limited submission by:  
Bristol Myers Squibb Pharmaceuticals Ltd**

**Advice No: 1810 – December 2010**

#### **Recommendation of AWMSG**

**Atazanavir (Reyataz<sup>®</sup>▼) capsules, co-administered with low dose ritonavir, are recommended as an option for use within NHS Wales for the treatment of HIV-1 infected paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products.**

**Atazanavir (Reyataz<sup>®</sup>▼) is not suitable for shared care within NHS Wales for the above indication.**

#### **Additional notes:**

The potential for drug interactions should be taken into consideration when prescribing.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion, lay perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be used without the whole of the advice being quoted in full and should be cited as: